Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mesenchymal stem cells from adipose tissue · 1 trial · 1 indication
Number of adverse events and serious adverse events: 24h administration of CeTMAd, 1 month, 3 months, 6 months, 9 months and 12 months.
| Arm | Type | Description |
|---|---|---|
| Low dose | EXPERIMENTAL | \- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight. |
| High dose | EXPERIMENTAL | \- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight. |
| Control | NO_INTERVENTION | Conventional treatment |
| Name | Type | Description |
|---|---|---|
| Mesenchymal stem cells from adipose tissue | OTHER | \- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight. |
Inclusion Criteria: * Patients of both sexes aged ≥ 18 and ≤ 89 years. * Nondiabetic. * Infrapopliteal atherosclerotic vascular disease of severe grade with either severe claudication or Rutherford-Becker grade II-III-IV, of at least one lower limb. It is defined critical ischemia of the lower limb...
Mesenchymal stem cells from adipose tissue is an investigational cell therapy being studied for Critical Limb Ischemia, a severe form of peripheral artery disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Design Therapeutics, Inc. (NASDAQ: DSGN) is the developer of Mesenchymal stem cells from adipose tissue. The company is conducting clinical research on this cell therapy for the treatment of Critical Limb Ischemia.
Mesenchymal stem cells from adipose tissue is in Phase 2 clinical development. It is an investigational therapy and has not received regulatory approval. One Phase 2 trial has been completed, with results not yet reported in this context.
Mesenchymal stem cells from adipose tissue has one completed Phase 2 trial, NCT01745744, which enrolled 33 patients with Critical Limb Ischemia in Spain. The trial was randomized and controlled with no treatment, and it included biomarker selection.
Mesenchymal stem cells from adipose tissue is a specific type of stem cell therapy derived from fat tissue, being tested for Critical Limb Ischemia. It is distinct from other stem cell sources, such as bone marrow-derived cells, and is being evaluated in clinical trials.